Rein Therapeutics (RNTX)

• Market cap: $60.6M
• 1 day: -0.76%
• 5 days: -14.38%
• 1 month: -16.55%
• 3 months: -25.7%
• 6 months: -48.38%
• Year to date: -43.83%
• 1 year: -38.95%
• 5 years: -96.75%
• 10 years: -99.67%
• Sector: Healthcare
• Industry: Biotechnology

About: Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Employees: 10